UroGen Pharma is trading $45.63 (+4.14%) after opening-session gains on September 9, 2026; no new company-specific announcement or explicit catalyst was identified.
- Management is scheduled to participate in a Wells Fargo healthcare conference at 3:00 PM ET, which may be supporting investor attention but does not establish causation.
- Healthcare is broadly weaker, making sector pressure inconsistent with this gain.